NASDAQ:NBIX - Nasdaq - US64125C1099 - Common Stock - Currency: USD
NASDAQ:NBIX (5/5/2025, 12:07:02 PM)
110.95
+1.27 (+1.16%)
The current stock price of NBIX is 110.95 USD. In the past month the price increased by 6.61%. In the past year, price decreased by -22.05%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.11 | 347.17B | ||
AMGN | AMGEN INC | 13.42 | 149.80B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1740.31 | 129.75B | ||
GILD | GILEAD SCIENCES INC | 13.29 | 128.09B | ||
REGN | REGENERON PHARMACEUTICALS | 13.7 | 65.52B | ||
ARGX | ARGENX SE - ADR | 344.27 | 39.94B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.91B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.26B | ||
BNTX | BIONTECH SE-ADR | N/A | 24.59B | ||
NTRA | NATERA INC | N/A | 21.56B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.79B | ||
BIIB | BIOGEN INC | 7.74 | 17.94B |
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. The company is headquartered in San Diego, California and currently employs 1,800 full-time employees. The firm is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa, and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
NEUROCRINE BIOSCIENCES INC
6027 Edgewood Bend Court
San Diego CALIFORNIA 92130 US
CEO: Kevin C. Gorman
Employees: 1800
Phone: 18586177600
The current stock price of NBIX is 110.95 USD. The price increased by 1.16% in the last trading session.
The exchange symbol of NEUROCRINE BIOSCIENCES INC is NBIX and it is listed on the Nasdaq exchange.
NBIX stock is listed on the Nasdaq exchange.
32 analysts have analysed NBIX and the average price target is 157.97 USD. This implies a price increase of 42.38% is expected in the next year compared to the current price of 110.95. Check the NEUROCRINE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NEUROCRINE BIOSCIENCES INC (NBIX) has a market capitalization of 10.98B USD. This makes NBIX a Large Cap stock.
NEUROCRINE BIOSCIENCES INC (NBIX) currently has 1800 employees.
NEUROCRINE BIOSCIENCES INC (NBIX) has a support level at 107.62 and a resistance level at 109.69. Check the full technical report for a detailed analysis of NBIX support and resistance levels.
The Revenue of NEUROCRINE BIOSCIENCES INC (NBIX) is expected to grow by 13.3% in the next year. Check the estimates tab for more information on the NBIX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NBIX does not pay a dividend.
NEUROCRINE BIOSCIENCES INC (NBIX) will report earnings on 2025-05-05, after the market close.
The PE ratio for NEUROCRINE BIOSCIENCES INC (NBIX) is 33.72. This is based on the reported non-GAAP earnings per share of 3.29 and the current share price of 110.95 USD. Check the full fundamental report for a full analysis of the valuation metrics for NBIX.
The outstanding short interest for NEUROCRINE BIOSCIENCES INC (NBIX) is 4.51% of its float. Check the ownership tab for more information on the NBIX short interest.
ChartMill assigns a technical rating of 2 / 10 to NBIX. When comparing the yearly performance of all stocks, NBIX is a bad performer in the overall market: 81.75% of all stocks are doing better.
ChartMill assigns a fundamental rating of 7 / 10 to NBIX. NBIX scores excellent points on both the profitability and health parts. This is a solid base for a good stock.
Over the last trailing twelve months NBIX reported a non-GAAP Earnings per Share(EPS) of 3.29. The EPS increased by 35.95% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 14.49% | ||
ROA | 9.18% | ||
ROE | 13.18% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to NBIX. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 27.36% and a revenue growth 13.3% for NBIX